In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Meda pays SEK21bn for family owned Italian company Rottapharm

Executive Summary

Meda AB, which recently fought off two unsolicited takeover bids from Mylan Inc. (the latest of which would have valued Meda at $6.7bn), paid SEK21bn ($3.1bn) for private, family owned Italian pharmaco Rottapharm SPA. The transaction excludes Rottapharm Biotech SRL, a separate entity (created in 2008 around assets purchased from Lay Line Genomics) focused on developing antibodies.
Deal Industry
  • Pharmaceuticals
    • Nutraceuticals
    • OTC, Consumer
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Payment Includes Cash
    • Payment Includes Stock

Related Companies